All Stories
Follow
Subscribe to Eckert & Ziegler Strahlen und Medizintechnik AG

Eckert & Ziegler Strahlen und Medizintechnik AG

ots Ad hoc-Service: Eckert & Ziegler AG <DE0005659700> Eckert & Ziegler with Record Results in Sales and Profits - New Projections

Berlin (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
In the previous fiscal year, Eckert & Ziegler AG, specialist for
low-level radioactive medical components, achieved the best result in
the history of the company with sales growing by 140% to just under
24 mio. EUR. According to the consolidated income statement published
on Wednesday for 2000, earnings before taxes in accordance with US
GAAP rose to more than 2.5 mio. EUR. The year before, the
Pankow-based company had reached only 21,000 EUR. The after-tax
result for 2000 is 1.3 mio. EUR which is equivalent to earnings per
share of 0.4 EUR. The balance sheet total of the company doubled to
50 mio. EUR, due to, among other factors, investments amounting to
roughly 20 mio. EUR. Besides new production plants and shareholdings,
they also included the acquisition of the Radiation Sources Business
of the American DuPont Pharmaceuticals Corporation. For the latter,
Eckert & Ziegler had placed a capital increase of approx. 18 mio. EUR
in summer. The rest could be covered through the cash flow from the
operating business, which reached 14% of sales, and through raising a
net credit of 2 mio. EUR. The equity ratio in the fiscal year rose
from 52 to 64%, liquid assets compared with the key date of the
previous year from four to 7% of the balance sheet total. Without the
cancellation of a large order which had already been completed and
the termination of the strategic alliance associated with it,
earnings before taxes in 2000 would have been substantially higher
since this resulted in a deficit in payment of 2,5 mio. US$,
explained the Chairman of the Board of the company, Dr. Andreas
Eckert. Instead we are now expecting a larger one-time compensation
payment for 2001, that will increase our earnings before taxes (EBIT)
to approx. 6 mio. EUR. Sales in the current fiscal year will now
amount to roughly 30 mio. EUR. In the following years up to 2003, we
expect annual growth rates of 30 % in EBIT and sales. The Board of
Directors
For further information please contact: Karolin Riehle, Investor
Relations Tel.: (+49 30) 94 10 84-0 www.ezag.de
End
Internet: http://recherche.newsaktuell.de

Original content of: Eckert & Ziegler Strahlen und Medizintechnik AG, transmitted by news aktuell

More stories: Eckert & Ziegler Strahlen und Medizintechnik AG
More stories: Eckert & Ziegler Strahlen und Medizintechnik AG